VEGFA and neoplasm: Other therapies including monoclonal antibody against VEGF, bevacizumab, that reduced tumor volume by targeting tumor vascularity, failed to demonstrate significant improvement in overall survival for patients already on taxane chemotherapy with prednisone [113,133].